// App-Quantinova.ai

e23035 : Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.

Researchers

Presenter

  • Marco Giallombardo

Principal Investigators

  • Jorge Jorge Chacartegui

  • Pablo Reclusa

  • Jan P. Van Meerbeeck

  • Riccardo Alessandro

  • Marc Peeters

  • Patrick Pauwels

  • Christian Diego Rolfo

Medical Centers

  • Phase I Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium, Edegem, Belgium

  • Phase I Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium, Edegem, Belgium

  • Phase I Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Edegem, Belgium, Edegem, Belgium

  • Department of Thoracic Oncology, University Hospital Antwerp, Edegem, Belgium

  • Department of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, Italy

  • Antwerp University Hospital, Edegem, Belgium

  • Antwerp Univ Hosp, Retie, Belgium

Locations

  • Italy

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Tagrisso

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved